Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 129

1.

Acquired rifampicin resistance in thrice-weekly antituberculosis therapy: impact of HIV and antiretroviral therapy.

Narendran G, Menon PA, Venkatesan P, Vijay K, Padmapriyadarsini C, Ramesh Kumar S, Bhavani KP, Sekar L, Gomathi SN, Chandrasekhar C, Kumar S, Sridhar R, Swaminathan S.

Clin Infect Dis. 2014 Dec 15;59(12):1798-804. doi: 10.1093/cid/ciu674. Epub 2014 Aug 25.

PMID:
25156114
2.

Efficacy of a 6-month versus 9-month intermittent treatment regimen in HIV-infected patients with tuberculosis: a randomized clinical trial.

Swaminathan S, Narendran G, Venkatesan P, Iliayas S, Santhanakrishnan R, Menon PA, Padmapriyadarsini C, Ramachandran R, Chinnaiyan P, Suhadev M, Sakthivel R, Narayanan PR.

Am J Respir Crit Care Med. 2010 Apr 1;181(7):743-51. doi: 10.1164/rccm.200903-0439OC. Epub 2009 Dec 3.

PMID:
19965813
3.

Long term follow up of HIV-infected patients with tuberculosis treated with 6-month intermittent short course chemotherapy.

Swaminathan S, Deivanayagam CN, Rajasekaran S, Venkatesan P, Padmapriyadarsini C, Menon PA, Ponnuraja C, Dilip M.

Natl Med J India. 2008 Jan-Feb;21(1):3-8.

PMID:
18472696
4.
5.
6.

Systemic exposure to rifampicin in patients with tuberculosis and advanced HIV disease during highly active antiretroviral therapy in Burkina Faso.

Saleri N, Dembélé SM, Villani P, Carvalho AC, Cusato M, Bonkoungou V, Nacanabo R, Kouanda S, Comelli M, Regazzi M, Matteelli A.

J Antimicrob Chemother. 2012 Feb;67(2):469-72. doi: 10.1093/jac/dkr445. Epub 2011 Oct 25.

PMID:
22028201
7.

Association between acquired rifamycin resistance and the pharmacokinetics of rifabutin and isoniazid among patients with HIV and tuberculosis.

Weiner M, Benator D, Burman W, Peloquin CA, Khan A, Vernon A, Jones B, Silva-Trigo C, Zhao Z, Hodge T; Tuberculosis Trials Consortium..

Clin Infect Dis. 2005 May 15;40(10):1481-91. Epub 2005 Apr 14.

PMID:
15844071
8.

Safety, efficacy and pharmacokinetics of ritonavir 400mg/saquinavir 400mg twice daily plus rifampicin combined therapy in HIV patients with tuberculosis.

Rolla VC, da Silva Vieira MA, Pereira Pinto D, Lourenço MC, de Jesus Cda S, Gonçalves Morgado M, Ferreira Filho M, Werneck-Barroso E.

Clin Drug Investig. 2006;26(8):469-79.

PMID:
17163279
9.

Safety and effectiveness of HAART in tuberculosis-HIV co-infected patients in Brazil.

dos Santos AP, Pacheco AG, Staviack A, Golub JE, Chaisson RE, Rolla VC, Kritski AL, Passos SR, de Queiroz Mello FC.

Int J Tuberc Lung Dis. 2013 Feb;17(2):192-7. doi: 10.5588/ijtld.11.0831.

10.
11.

Treatment of tuberculosis in HIV-infected persons in the era of highly active antiretroviral therapy.

Dean GL, Edwards SG, Ives NJ, Matthews G, Fox EF, Navaratne L, Fisher M, Taylor GP, Miller R, Taylor CB, de Ruiter A, Pozniak AL.

AIDS. 2002 Jan 4;16(1):75-83.

PMID:
11741165
12.

Improved outcomes of HIV-1-infected adults with tuberculosis in the era of highly active antiretroviral therapy.

Hung CC, Chen MY, Hsiao CF, Hsieh SM, Sheng WH, Chang SC.

AIDS. 2003 Dec 5;17(18):2615-22.

PMID:
14685055
13.

Efficacy of the 6-month thrice-weekly regimen in the treatment of new sputum smear-positive pulmonary tuberculosis under clinical trial conditions.

Banu Rekha VV, Rajaram K, Kripasankar AS, Parthasarathy R, Umapathy KC, Sheikh I, Selvakumar N, Victor M, Niruparani C, Sridhar R, Jawahar MS.

Natl Med J India. 2012 Jul-Aug;25(4):196-200.

PMID:
23278775
14.
15.

Effectiveness of anti-tuberculosis treatment among patients receiving highly active antiretroviral therapy at Vihiga district hospital in 2007.

Kwange SO, Budambula NL.

Indian J Med Microbiol. 2010 Jan-Mar;28(1):21-5. doi: 10.4103/0255-0857.58723.

16.

Randomised trial of isoniazid versus rifampicin and pyrazinamide for prevention of tuberculosis in HIV-1 infection.

Halsey NA, Coberly JS, Desormeaux J, Losikoff P, Atkinson J, Moulton LH, Contave M, Johnson M, Davis H, Geiter L, Johnson E, Huebner R, Boulos R, Chaisson RE.

Lancet. 1998 Mar 14;351(9105):786-92.

PMID:
9519950
17.

Outcome of HIV-associated tuberculosis in the era of highly active antiretroviral therapy.

Dheda K, Lampe FC, Johnson MA, Lipman MC.

J Infect Dis. 2004 Nov 1;190(9):1670-6. Epub 2004 Sep 29.

PMID:
15478074
18.

Miliary tuberculosis in human immunodeficiency virus infected patients not on antiretroviral therapy: clinical profile and response to shortcourse chemotherapy.

Swaminathan S, Padmapriyadarsini C, Ponnuraja C, Sumathi CH, Rajasekaran S, Amerandran VA, Reddy M, Deivanayagam CN.

J Postgrad Med. 2007 Oct-Dec;53(4):228-31.

19.

Impact of antiretroviral therapy on the incidence of tuberculosis: the Brazilian experience, 1995-2001.

Miranda A, Morgan M, Jamal L, Laserson K, Barreira D, Silva G, Santos J, Wells C, Paine P, Garrett D.

PLoS One. 2007 Sep 5;2(9):e826.

20.

Twice-weekly, directly observed treatment for HIV-infected and uninfected tuberculosis patients: cohort study in rural South Africa.

Davies GR, Connolly C, Sturm AW, McAdam KP, Wilkinson D.

AIDS. 1999 May 7;13(7):811-7.

PMID:
10357380

Supplemental Content

Support Center